The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor fluorescence in situ hybridisation-positive (EGFR FISH+) metastatic colorectal cancer patients (mCRC) has not been previously investigated. In the present study, we analysed KRAS, BRAF, PI3KCA, MET, and IGF1R in 85 mCRC treated with cetuximab-based therapy in whom EGFR status was known. KRAS mutations (52.5%) negatively affected response only in EGFR FISH+ patients. EGFR FISH+/KRAS mutated had a significantly lower response rate (P = 0.04) than EGFR FISH+/KRAS wild type patients. Four EGFR FISH+ patients with KRAS mutations responded to cetuximab therapy. BRAF was mutated in 5.0% of patients and none responded to the therapy. PI3KCA mutations (17.7%) were not associated to cetuximab sensitivity. Patients overexpressing IGF1R (74.3%) had significantly longer survival than patients with low IGF1R expression (P = 0.006), with no difference in response rate. IGF1R gene amplification was not detected, and only two (2.6%) patients, both responders, had MET gene amplification. In conclusion, KRAS mutations are associated with cetuximab failure in EGFR FISH+ mCRC, even if it does not preclude response. The rarity of MET and IGF1R gene amplification suggests a marginal role in primary resistance. The potential prognostic implication of IGF1R expression merits further evaluation.
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients / F. Cappuzzo, M. Varella-Garcia, G. Finocchiaro, M. Skokan, S. Gajapathy, C. Carnaghi, L. Rimassa, E. Rossi, C. Ligorio, L. Di Tommaso, A.J. Holmes, L. Toschi, G. Tallini, A. Destro, M. Roncalli, A. Santoro, P.A. Jänne. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 99:1(2008 Jul 08), pp. 83-89.
|Titolo:||Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients|
|Parole Chiave:||Antibodies, Monoclonal ; Antineoplastic Agents ; Colorectal Neoplasms ; Drug Resistance, Neoplasm ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Middle Aged ; Nuclear Proteins ; Proto-Oncogene Proteins ; Proto-Oncogene Proteins B-raf ; Proto-Oncogene Proteins c-met ; Receptor, Epidermal Growth Factor ; Receptors, Growth Factor ; Receptors, Somatomedin; Transcription Factors ; ras Proteins|
|Settore Scientifico Disciplinare:||Settore MED/08 - Anatomia Patologica|
Settore MED/06 - Oncologia Medica
|Data di pubblicazione:||8-lug-2008|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/sj.bjc.6604439|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Cappuzzo et al. Primary resistence to cetuximab.pdf||Publisher's version/PDF||Administrator Richiedi una copia|